The current corona pandemic poses major challenges for manufacturing companies in highly regulated industries such as pharmaceuticals, biotech, fine chemicals and medical technology. In addition to the general concern for the health of employees, there are organisational difficulties such as bottlenecks due to absent staff and a simultaneous sharp increase in the demand for medicines, protective clothing, disinfectants and their basic materials. In order to continue to reliably meet this demand, production in these areas must be ramped up to a maximum, which requires additional personnel.